Autologous and allogeneic transplantation for aggressive NHL

References

• Cartwright R, Brincker H, Carli PM et al. The rise in inci-dence of lymphomas in Europe 1985-1992. Eur 7 Cancer 1999;35:627–33.
   PubMed Web of Science ®Google Scholar
• Groves FD, Linet MS, Travis LB, Devesa SS. Cancer sur-veillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. yNatl Cancer Inst 2000;92:1240–51.
   PubMed Web of Science ®Google Scholar
• Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl .7 Med 1993;328:1023–30.
   PubMed Web of Science ®Google Scholar
• Frei E, III, Blum RH, Pitman SW et al. High dose metho-trexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am y Med 1980;68:370–6.
   Google Scholar
• Bosly A, Coiffier B, Gisselbrecht C et al. Bone marrow trans-plantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. Clin Oncol 1992;10:1615–23.
   Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl Med 1987;316:1493–8.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. 7 Clin Oncol 1 993;11:2351-61.
   Google Scholar
• Saez R, Dahlberg S, Appelbaum FR et al. Autologous bone marrow transplantation in adults with non-Hodgkin's lym-phoma: a Southwest Oncology Group study. Hematol Oncol 1994;12:75–85.
   PubMed Web of Science ®Google Scholar
• Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. Clin Onco/1993;11:1846–51.
   Web of Science ®Google Scholar
• Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl .7 Med 1987;316: 1499–1505.
   Google Scholar
• van Besien K, Tabocoff J, Rodriguez M et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549–55.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl y Med 1995;333:1540–5.
   PubMed Web of Science ®Google Scholar
• Blay J, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562–8.
   Google Scholar
• Anonymous. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl 3 Med 1993;329:987–94.
   Google Scholar
• van Besien K, Rodriguez A, Tomany S et al. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 2001;27:397–404.
   Google Scholar
• Guglielmi C, Gomez F', Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. .7 Clin 0nco11998;16: 3269–9.
   Google Scholar
• Guglielmi C, Martelli M, Federico M et al. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Haematologica 2001;86:941–50.
   Google Scholar
• Moskowitz CH, Nimer SD, Glassman JR et al. The International Prognostic Index predicts for outcome follow-ing autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lym-phoma. Bone Marrow Transplant 1999;23:561–7.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospectiveLNH87-2 protocol — a groupe d'Etude des lymphomes de l'Adulte study. 7 Clin Oncol 2000;18:3025–30.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, van Putten WL, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl 7 Med 1995;332:1045–51.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S et at High-dose chemother-apy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl med 1997;336:1290–7.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. 7 Natl Cancer Inst 2001;93:22–30.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Morel P et al. Failure of first-line induc-tive high-dose chemotherapy in poor risk patients with aggressive lymphoma: updated results of the randomized LNH93-3 study [abstract]. Blood 1997;90 (Suppl 1):594a (abstr 2640).
   Google Scholar
• Kaiser U, Uebelacker I, Birkmann J, Havemann K. High dose therapy with autologous stem cell transplantation in aggressive NHL: results of a randomized multicenter study [abstract]. Blood 2001;94 (Suppl. 1):# 2716.
   Google Scholar
• Vitolo U, Liberati A, Deliliers G et al. A multicenter ran-domized trial by Italian Lymphoma Intergroup (ILI) com-paring high dose chemotherapy (hds) with autologous stem cell transplantation (ASCT) vs intensified chemotherapy megaceop in high risk diffuse large cell lymphoma (DLCL): no difference in outcome and toxicity. [abstract]. Blood 2001;98 (Suppl 1):#3028.
   Google Scholar
• Martelli M, Vignetti M, Zinzani PL et al. High-dose chemotherapy followed by autologous bone marrow trans-plantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective random-ized italian multicenter study. 7 Clin Oncol1996;14: 539–42.
   Google Scholar
• Fisher RI. Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. 7 Natl Cancer Inst 2001;93:4–5.
   PubMedGoogle Scholar
• Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Clin °new/ 1995;13:588–95.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplanta-tion for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399–404.
   PubMed Web of Science ®Google Scholar
• Vose JM, Zhang MJ, Rowlings PA et al. Autologous trans-plantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. 7 Clin Oncol2001;19: 406–13.
   Google Scholar
• Champlin RE. Peripheral blood progenitor cells: a replace-ment for marrow transplantation? Semin Oncol 1996; 23:15–21.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Singer J, Appelbaum F et al. Autologous trans-plantation with peripheral blood mononuclear cells col-lected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158–63.
   PubMed Web of Science ®Google Scholar
• Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031–5.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell trans-plantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353–7.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Agthoven M, Croockewit AJ et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br y Haematol 2001;114:319–26.
   PubMed Web of Science ®Google Scholar
• Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized com-parison. 7 Clin Oncol 1995;13:1328–35.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997;90:4212–21.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Price CG, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. 7 Clin Oncol1994;12:798–805.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449–57.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Joshi SS, Armitage JO et al. Significance of detec-tion of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992;79:1074–80.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Kessinger A, Mann S et al. Outcome of high-dosetherapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. 7 Clin Oncol1996;14:219–19.
   Web of Science ®Google Scholar
• Jacquy C, Soree A, Lambert F et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients signifi-cantly mobilize malignant cells. Br 7 Haematol 2000;110:631–7.
   PubMed Web of Science ®Google Scholar
• Demirkazik A, Kessinger A, Armitage JO et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 2001;28:207–12.
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C, Mangoni L, Almici C et al. Use of recombi-nant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. Blood 1992;80:2412–18.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Coiffier B, Hayat M et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992;80:1149–57.
   PubMed Web of Science ®Google Scholar
• Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. 7 Clin Oncol 1996; 14:2459–64.
   Web of Science ®Google Scholar
• Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation—results of a retrospective analysis on 120 patients auto-grafted in a single institution. 7 Clin 0nco11998;16: 2803–16.
   Google Scholar
• Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ periph-eral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998;4: 84–92.
   Google Scholar
• Vose JM, Bierman PJ, Lynch JC et al. Transplantation of highly purified CD34+ Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2001;7:680–7.
   PubMed Web of Science ®Google Scholar
• Buckstein R, Imrie K, Spaner D et at Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999;26:115–22.
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000;96:869–9.
   Web of Science ®Google Scholar
• Flinn IW, Lazarus HM. Monoclonal antibodies and autolo-gous stem cell transplantation for lymphoma. Bone Marrow Transplant 2001;27:565–9.
   PubMed Web of Science ®Google Scholar
• Salar A, Sierra J, Gandarillas M et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001;27:405–12.
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998;9 (Suppl 1):515–521.
   Google Scholar
• Stiff PJ, Dahlberg S, Forman SJ et at Autologous bone mar-row transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of aug-mented preparative regimens—a Southwest Oncology Group trial. 7 Clin Oncol 1998;16:48–55.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Delgado F, Maloney DG, Press OW et al. Autologous stem cell transplantation for non-Hodgkin'slymphoma: comparison of radiation-based and chemother-apy-only preparative regimens. Bone Marrow Transplant 2001;28:455–61.
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-anti-body therapy of B-cell lymphoma with autologous bone marrow support. N Engl .7 Med 1993;329: 1219–24.
   Google Scholar
• Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131—tositumomab (anti-C D20), etoposide, cyclo - phosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2939–42.
   Web of Science ®Google Scholar
• Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsedB-cell lymphoma patients treated with iodine-131- labeled anti-C D20 antibody and autologous stem-cell rescue. 7 Clin Oncol 1998;16: 3270–8.
   Google Scholar
• Le Beau MM, Albain KS, Larson RA et al. Clinical and cyto-genetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. y C/in Onco/ 1986;4:325–45.
   PubMed Web of Science ®Google Scholar
• Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dys-myelopoietic syndromes in patients with previously treated malignant disease. Blood 1981;58:759–67.
   Google Scholar
• Lillington DM, Micallef IN, Carpenter E et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. 7 Clin Oncol 2001;19:2472–81.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malig-nancies. 7 Clin Oncol2000;18: 947–55.
   Google Scholar
• Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplanta-tion for lymphoid malignancies. .7 Clin Oncol 1994; 12:2527–34.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodyspla-sia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273–9.
   Google Scholar
• Traweek ST, Slovak ML, Nademanee AP et at Clonal kary-otypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's dis-ease and non-Hodgkin's lymphoma. Blood 1994;84:957–63.
   PubMed Web of Science ®Google Scholar
• Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. 7 Clin Oncol 1992;10:1690–5.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77: 649–53.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994;84:1050–5.
   PubMed Web of Science ®Google Scholar
• van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am yMed 1996;100:299–307.
   PubMed Web of Science ®Google Scholar
• Goldstein SC, Perkins J, Janssen WE et al. A prospective, Comparative Trial of High Dose Therapy Followed by Allogeneic versus Autologous Stem Cell Transplantation in 100 Patients with High Risk Lymphoma [abstract]. Blood 2001;98 (Suppl 1):#1754.
   Google Scholar
• van Besien KW, de Lima M, Giralt SA et at Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997;19:977–82.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malig-nancy. Ann 0nco11999;10:1293–9.
   Google Scholar
• Dhedin N, Giraudier S, Gaulard P et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lym-phoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br y Haematol 1999;107:159–61.
   Web of Science ®Google Scholar
• Mitterbauer M, Neumeister P, Kalhs P et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001;15:635–41.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Freedman AS, Neuberg D et al. CD6 T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21:1177–81.
   PubMed Web of Science ®Google Scholar
• van Besien K, Thall P, Korbling M et al. Allogeneic trans-plantation for recurrent or refractory non-Hodgkin's lym-phoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997;3:150–6.
   PubMedGoogle Scholar
• Przepiorka D, van Besien K, Khouri I et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regi-men for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999;10:527–32.
   PubMed Web of Science ®Google Scholar
• Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regi-mens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br y Haematol 2000;111:18–29.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. 7 Clin Oncol 1998;16: 2817–24.
   Google Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89: 4531–6.
   PubMed Web of Science ®Google Scholar
• Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic trans-plantation. Bone Marrow Transplant 2001;27 (Suppl 2): S13—S22.
   Google Scholar
• Spitzer TR, McAfee SL, Dey BR et al. Durable progression free survival (PFS) following non-myeloablative bone mar-row transplantation (BMT) for chemorefractory diffuse large B cell lymphoma (B-LCL) [abstract]. Blood 2001;98 (Suppl 1):#2813.
   Google Scholar
• Kyriakou CA, Milligan D, Chopra R et al. Outcome of non-myeloablative stem cell transplantation for NHL is depen-dent on histology good for patients with low grade disease and poor for those with high grade lymphoma. [abstract]. Blood 2001;98 (Suppl 1):#1737.
   Google Scholar
• Lichtenstein AK, Levine A, Taylor CR et al. Primary medi-astinal lymphoma in adults. Am y Med 1980;68:509–14.
   PubMed Web of Science ®Google Scholar
• Miller JB, Variakojis D, Bitran JD et al. Diffuse histiocytic lymphoma with sclerosis: a clinicopathologic entity fre-quently causing superior venacaval obstruction. Cancer 1981;47:748–56.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. y Clin Oneo/2001;19:1855–64.
   Google Scholar
• Popat U, Przepiork D, Champlin R et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. y Gun 0nco11998;16: 63–9.
   Google Scholar
• Sehn LH, Antin JH, Shulman LN et al. Primary diffuse largeB-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998;91:717–23.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follic-ular lymphoma patients. y Clin Oncol 1997;15:1587–94.
   PubMed Web of Science ®Google Scholar
• Garvin AJ, Simon RM, Osborne CK et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer 1983;52:393–8.
   Google Scholar
• Acker B, Hoppe RT, Colby TV et al. Histologic conversion in the non-Hodgkin's lymphomas. yClin Oncol 1 983;1:11–16.
   Google Scholar
• Cao TM, Horning S, Negrin RS et al. High-dose therapy and autologous hematopoietic-cell transplantation for fol-licular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001;7:294–301.
   PubMed Web of Science ®Google Scholar
• Williams CD, Harrison CN, Lister TA et al. High-dose ther-apy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lym-phoma: a case-matched study from the European Bone Marrow Transplant Registry y Clin Oncol 2001;19:727–35.
   Google Scholar
• Nebraska Lymphoma Study Group. Am y Hematol 2000;64:190-6.therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998;9:
   Google Scholar
• Weisenburger DD, Armitage JO. Mantle cell lymphoma — an entity comes of age. Blood 1996;87:4483–94.
   PubMed Web of Science ®Google Scholar
• Majlis A, Pugh WC, Rodriguez MA et al. Mantle cell lym-
   Google Scholar
• Oinonen R, Franssila K, Teerenhovi L et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur y Cancer 1998;34:329–36.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Vose JM, Greiner TC et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from theNebraska Lymphoma Study Group. Am J Hematol 2000;64:190–6.
   Google Scholar
• Vandenberghe E, de Elvira CR, Isaacson P et al. Does transplantation improve outcome in mantle cell lymphoma? Astudy from the EBMT. Blood 2000;96 (Suppl 1):#2072.
   Google Scholar
• Khouri I, Romaguera J, Kantarjian H et al. Hyper-CVADand high dose methotrexate/cytarabine followed by stemcell transplantation: an active regimen for aggressive mantlecell lymphoma. J Clin Oncol 1998;16:3803–9.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Espinouse D et al. Intensive therapywith peripheral stem cell transplantation in 16 patients withmantle cell lymphoma. Ann Oncol 1997;8:701–4.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Neuberg D, Gribben JG et al. High-dosechemoradiotherapy and anti-B-cell monoclonal antibodypurgedautologous bone marrow transplantation in mantlecelllymphoma: no evidence for long-term remission. J ClinOncol 1998;16:13–18.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Weisenburger DD et al. Autologoushematopoietic stem cell transplantation for mantle celllymphoma. Biol Blood Marrow Transplant 2000;6:640–5.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Brousse N, Brice P et al. Efficacy of autologous\stem cell transplantation in mantle cell lymphoma:a 3-year follow-up study. Bone Marrow Transplant 2000;25:251–6.
   PubMed Web of Science ®Google Scholar
• Milpied N, Gaillard F, Moreau P et al. High-dose therapy\with stem cell transplantation for mantle cell lymphoma:results and prognostic factors, a single center experience.\Bone Marrow Transplant 1998;22:645–50.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Sebban C, Surbiguet C et al. High-dosechemotherapy with hematopoietic stem cell transplantationin patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphoma. A single center experience on 18patients. Bone Marrow Transplant 1998;21: 51–4.
   Google Scholar
• Jacquy C, Lambert F, Soree A et al. Peripheral blood stem\cell contamination in mantle cell non-Hodgkin lymphoma:the case for purging? Bone Marrow Transplant 1999;23:681–6.
   PubMed Web of Science ®Google Scholar
• Kroger N, Hoffknecht M, Kruger W et al. Allogeneic bonemarrow transplantation for refractory mantle cell lymphoma.Ann Hematol 2000;79:578–80.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Astolfi M et al. Clinical and molecularremission after allogeneic blood cell transplantation ina patient with mantle-cell lymphoma. Br J Haematol1996;94:376–8.
   PubMed Web of Science ®Google Scholar
• Martinez C, Carreras E, Rovira M et al. Patients with mantle-cell lymphoma relapsing after autologous stem celltransplantation may be rescued by allogeneic transplantation.Bone Marrow Transplant 2000;26:677–9.
   PubMedGoogle Scholar
• Sohn SK, Baek JH, Kim DH et al. Successful allogeneicstem-cell transplantation with prophylactic stepwise GCSF\primed-DLIs for relapse after autologous transplantationin mantle cell lymphoma: a case report and literaturereview on the evidence of GVL effects in MCL. Am JHematol 2000;65:75–80.
   PubMedGoogle Scholar
• Stein H, Foss HD, Durkop H et al. CD30(1 ) anaplastic largecell lymphoma: a review of its histopathologic, genetic, andclinical features. Blood 2000;96:3681–95.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-celllymphomas have a worse prognosis than B-cell lymphomas:a prospective study of 361 immunophenotyped patientstreated with the LNH-84 regimen. The GELA (Grouped’Etude des Lymphomes Agressives). Ann Oncol1990;1:45–50.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significanceof T-cell phenotype in aggressive non-Hodgkin’slymphomas. Groupe d’Etudes des Lymphomes de l’Adulte(GELA). Blood 1998;92:76–82.
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodriguez A, Pugh WC, Cabannillas F.Evaluation of the Revised European-American Lymphomaclassification confirms the clinical relevance ofimmunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 1997;89: 4514–20.
   Google Scholar
• Blystad AK, Enblad G, Kvaloy S et al. High-dose therapywith autologous stem cell transplantation in patients withperipheral T cell lymphomas. Bone Marrow Transplant2001;27:711–16.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Munsell M, Yazji S et al. Impact of high-dosechemotherapy on peripheral T-cell lymphomas. J Clin Oncol2001;19:3766–70.
   PubMed Web of Science ®Google Scholar
• Vose JM, Peterson C, Bierman PJ et al. Comparison of highdosetherapy and autologous bone marrow transplantationfor T-cell and B-cell non-Hodgkin’s lymphomas. Blood1990;76:424–31.
   PubMed Web of Science ®Google Scholar
• Nademanee A, Molina A, O’Donnell MR et al. Results ofhigh-dose therapy and autologous bone marrow/stem celltransplantation during remission in poor-risk intermediate-and high-grade lymphoma: international index highand high-intermediate risk group. Blood 1997;90:3844–52.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Pearce R, Taghipour G et al. AdultBurkitt’s and Burkitt-like non-Hodgkin’s lymphoma—outcome for patients treated with high-dose therapyand autologous stem-cell transplantation in first remissionor at relapse: results from the European Groupfor Blood and Marrow Transplantation. J Clin Oncol1996;14:2465–72.
   PubMed Web of Science ®Google Scholar
• Ostronoff M, Soussain C, Zambon E et al. Burkitt's lym-phoma in adults: a retrospective study of 46 cases. Nouv Rev Er Hemato/1992;34:389–97.
   PubMedGoogle Scholar
• Petersen FB, Appelbaum FR, Bigelow CL et al. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow Transplant 1989;4:483–8.
   PubMed Web of Science ®Google Scholar
• Philip T, Meckenstock R, Deconnick E et al. Treatment of poor prognosis Burkitt's lymphoma in adults with the Societe Francaise d'Oncologie Pediatrique LMB Protocol—a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur 7 Cancer 1992;28A:1959–9.
   PubMed Web of Science ®Google Scholar
• Troussard X, Leblond V, Kuentz M et al. Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remis-sion. 7 Clin Onco/1990;8:809–12.
   PubMed Web of Science ®Google Scholar
• Milpied N, Ifrah N, Kuentz M et al. Bone marrow transplan-tation for adult poor prognosis lymphoblastic lymphoma in first complete remission. BryHaematol 1989; 7 3:8 2–7.
   Google Scholar
• Santini G, Coser P, Chisesi T et at Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of theNon-Hodgkin's Lymphoma Cooperative Study Group (NHLC SG). Ann Onco/1991;2 (Suppl 2):181–5.
   Google Scholar
• Sweetenham JW, Liberti G, Pearce R et al. High-dose ther-apy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. 7 Clin Oncol 1994;12: 1358–65.
   Google Scholar
• Verdonck LF, Dekker AW, de Gast GC et al. Autologous bone marrow transplantation for adult poor-risk lym-phoblastic lymphoma in first remission. 7 Gun Oncol 1992;10:649–6.
   Google Scholar
• Sweetenham JW, Santini G, Qtan W et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. 7 Clin Oncol 2001; 19:2927–36.
   PubMed Web of Science ®Google Scholar
• Bouabdallah R, Xerri L, Bardou VJ et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 1998;9:619–25.
   PubMed Web of Science ®Google Scholar